Target intelligence / Profile preview

ATPase H+ transporting V0 subunit a2 (ATP6V0A2)

Target
ATP6V0A2
Molecular classification
Enzyme, Transporter
01

Overview

ATPase H+ transporting V0 subunit a2 (ATP6V0A2) is a critical component of the vacuolar H+-ATPase (V-ATPase) complex, an evolutionary conserved proton pump responsible for the acidification of intracellular compartments. It is primarily localized to the Golgi apparatus and endosomes, where it maintains the acidic environment necessary for essential post-translational modifications, particularly N- and O-linked glycosylation, and efficient vesicular trafficking (Creative Biolabs, 2024; UniProt, 2024). Mutations in the ATP6V0A2 gene are the primary cause of Autosomal Recessive Cutis Laxa Type IIA (ARCL2A) and Wrinkly Skin Syndrome, which are characterized by skin inelasticity, skeletal abnormalities, and developmental delays due to impaired tropoelastin secretion and glycosylation defects (NIH, 2026; ResearchGate, 2026). In the context of oncology, ATP6V0A2 has been implicated in tumor-associated macrophage maturation and resistance to chemotherapeutic agents like cisplatin, suggesting its potential as a therapeutic target for modulation (NIH, 2026). Therapeutic strategies involving ATP6V0A2 mRNA include mRNA-based protein replacement therapy to restore function in genetic deficiency syndromes and RNA interference (RNAi) to downregulate its expression in cancer-related contexts (NIH, 2025; News-Medical, 2025).

Other names
V-type proton ATPase subunit a2Autosomal recessive cutis laxa type IIAARCL2AWrinkly skin syndromeWSSJ6S1STV1Regeneration and tolerance factorRTFV-type proton ATPase 116 kDa subunit a isoform 2
02

Mechanism of action

V-ATPase inhibition; mRNA-based protein replacement; RNA interference-mediated gene silencing

03

Biological functions

Intracellular acidificationProtein glycosylationVesicle traffickingTropoelastin secretionIron homeostasisCellular senescence
04

Disease associations

Autosomal Recessive Cutis Laxa Type IIAWrinkly Skin SyndromeCongenital Disorder of GlycosylationCancerDe Barsy Syndrome
05

Safety considerations

Systemic V-ATPase inhibition toxicityImmunogenicity of synthetic mRNATissue-specific delivery challengesOff-target effects of RNA interference
06

Interacting drugs

Bafilomycin A1

1 more in the full profile.

07

Biomarkers

Serum transferrin glycosylationTropoelastin aggregationGolgi pHATP6V0A2 mRNA expression

Beyond the preview

Go deeper on ATPase H+ transporting V0 subunit a2 (ATP6V0A2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATPase H+ transporting V0 subunit a2 (ATP6V0A2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call